Scarica l'app Stockscreener
5.23
6.77%
-0.38
Precedente Chiudi:
$5.61
Aprire:
$5.625
Volume 24 ore:
5.08M
Relative Volume:
1.41
Capitalizzazione di mercato:
$512.47M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+0.19%
1M Prestazione:
-1.32%
6M Prestazione:
+45.28%
1 anno Prestazione:
+188.95%
Intervallo 1D:
$5.14
$5.69
Intervallo di 1 settimana:
$5.08
$5.745
Portata 52W:
$1.67
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
5.23 | 499.31M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-18 | Iniziato | Leerink Partners | Outperform |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Iniziato | Wells Fargo | Overweight |
| 2024-09-05 | Iniziato | Jefferies | Buy |
| 2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-09-21 | Iniziato | Piper Sandler | Overweight |
| 2021-05-10 | Iniziato | Laidlaw | Buy |
| 2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Iniziato | ROTH Capital | Buy |
| 2020-03-02 | Iniziato | Oppenheimer | Outperform |
| 2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Iniziato | Piper Jaffray | Overweight |
| 2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Iniziato | Citigroup | Neutral |
| 2015-06-01 | Iniziato | Citigroup | Buy |
| 2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
Will aTyr Pharma Inc. Bounce From 52 Week LowPotential Breakout Stock List Published This Week - 선데이타임즈
aTyr Pharma Inc. Outperforms Peers on Volume MetricsSwing Setup With Technical Confirmation Explained - 선데이타임즈
aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
aTyr Pharma Inc. Shows Support at Fibonacci LevelAI Based High Gain Watchlist Scanner Shared - beatles.ru
Traders Consider Averaging Down in aTyr Pharma Inc.Entry Alert Based on Volume Spikes Detected - metal.it
Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma - TipRanks
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
Connect Biopharma Holdings Limited shares rise 1.93% intraday after aTyr Pharma announced Phase 3 EFZO-FIT™ study completion. - AInvest
3 Innovation Stocks With Parabolic Upside Potential - AOL.com
aTyr Pharma Reports Q2 2025 Financial Results - TipRanks
Atyr Pharma: Q2 Earnings Snapshot - Stamford Advocate
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update - GlobeNewswire
aTyr Pharma reports Q2 EPS (22c), consensus (18c) - TipRanks
Major Phase 3 Milestone: aTyr's Pulmonary Sarcoidosis Drug Shows Promise as 268-Patient Trial Wraps Up - Stock Titan
aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks
aTyr Pharma stock awaits key Phase 3 trial results, Cantor Fitzgerald maintains Overweight rating - Investing.com Canada
aTyr Pharma stock rating reiterated by Cantor Fitzgerald ahead of trial data - Investing.com Canada
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth? - Yahoo Finance
Should I hold or sell aTyr Pharma Inc. stock in 2025Free Trading Psychology Coaching - Jammu Links News
Is it the right time to buy aTyr Pharma Inc. stockOutstanding risk-reward balance - Jammu Links News
What drives aTyr Pharma Inc. stock priceDiscover stocks with explosive growth potential - Jammu Links News
What are the technical indicators suggesting about aTyr Pharma Inc.Invest confidently with professional market insights - Jammu Links News
What analysts say about aTyr Pharma Inc. stockAchieve exceptional returns with expert guidance - Jammu Links News
What makes aTyr Pharma Inc. stock price move sharplyDiscover high-impact stocks for your portfolio - Jammu Links News
How does aTyr Pharma Inc. generate profit in a changing economyMaximize your gains with expert trading tips - Jammu Links News
Is aTyr Pharma Inc. stock overvalued or undervaluedBuild a portfolio that withstands market volatility - Jammu Links News
What institutional investors are buying aTyr Pharma Inc. stockCapitalize on fast-moving stock opportunities - Jammu Links News
Is aTyr Pharma Inc. in Accumulation Phase NowExpert Verified Stock Trade Ideas Backed by Data - metal.it
Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here? - Barchart.com
Price Channel Expanding on aTyr Pharma Inc.’s ChartReal Time Stock Movement Analysis Indicates Breakout - metal.it
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), aTyr Pharma (ATYR) and HCA Healthcare (HCA) - The Globe and Mail
Price Consolidation Hints at Upcoming Move in aTyr Pharma Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Wyckoff Accumulation Phase Possible in aTyr Pharma Inc.Entry Plan for Oversold Reversal Stocks Released - metal.it
Will aTyr Pharma Inc. Recover After Recent DeclineMarket Momentum Signal Generator Shows Trends - metal.it
Published on: 2025-07-29 07:01:04 - beatles.ru
aTyr Pharma Inc. Breakout Confirmed by Volume MetricsWatchlist for Smart Swing Trading Updated - metal.it
aTyr Pharma Stock Faces Market Scrutiny Amid Financial Challenges - StocksToTrade
aTyr Pharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Entry and Exit Point Tips From Traders - metal.it
What is aTyr Pharma Inc. company’s growth strategyMaximize returns with data-driven strategies - Jammu Links News
What are aTyr Pharma Inc. company’s key revenue driversGet daily updates on the hottest stocks - Jammu Links News
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):